Steven A. J.  Salamon net worth and biography

Steven Salamon Biography and Net Worth

Director of Delcath Systems
Steven Salamon is a co-founder and Portfolio Manager at Rosalind Advisors, Inc., a life sciences focused investment manager established in 2006 (“Rosalind Advisors”). Rosalind Advisors is the investment manager for the Rosalind Funds. Mr. Salamon holds a MBA from the Ivey Business School and an Engineering Physics degree from the University of Toronto. Prior to co-founding Rosalind Advisors, Mr. Salamon worked as an equity analyst at HSBC Securities and RBC Capital Markets (formerly RBC Dominion Securities).

What is Steven A. J. Salamon's net worth?

The estimated net worth of Steven A. J. Salamon is at least $142,117.92 as of May 12th, 2022. Mr. Salamon owns 29,424 shares of Delcath Systems stock worth more than $142,118 as of March 28th. This net worth approximation does not reflect any other assets that Mr. Salamon may own. Learn More about Steven A. J. Salamon's net worth.

How do I contact Steven A. J. Salamon?

The corporate mailing address for Mr. Salamon and other Delcath Systems executives is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. Delcath Systems can also be reached via phone at 212-489-2100 and via email at [email protected]. Learn More on Steven A. J. Salamon's contact information.

Has Steven A. J. Salamon been buying or selling shares of Delcath Systems?

Steven A. J. Salamon has not been actively trading shares of Delcath Systems within the last three months. Most recently, on Thursday, May 12th, Steven A. J. Salamon bought 6,000 shares of Delcath Systems stock. The stock was acquired at an average cost of $4.90 per share, with a total value of $29,400.00. Following the completion of the transaction, the director now directly owns 29,424 shares of the company's stock, valued at $144,177.60. Learn More on Steven A. J. Salamon's trading history.

Who are Delcath Systems' active insiders?

Delcath Systems' insider roster includes Gerard Michel (CEO), John Purpura (COO), and Steven Salamon (Director). Learn More on Delcath Systems' active insiders.

Are insiders buying or selling shares of Delcath Systems?

During the last twelve months, Delcath Systems insiders bought shares 8 times. They purchased a total of 295,583 shares worth more than $857,284.88. The most recent insider tranaction occured on March, 19th when Director Gil Aharon bought 26,882 shares worth more than $100,001.04. Insiders at Delcath Systems own 21.1% of the company. Learn More about insider trades at Delcath Systems.

Information on this page was last updated on 3/19/2024.

Steven A. J. Salamon Insider Trading History at Delcath Systems

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/12/2022Buy6,000$4.90$29,400.0029,424View SEC Filing Icon  
4/19/2022Buy1,600$6.25$10,000.00429,100View SEC Filing Icon  
6/30/2021Buy5,500$12.76$70,180.00View SEC Filing Icon  
6/28/2021Buy5,000$11.56$57,800.00View SEC Filing Icon  
6/24/2021Buy4,500$10.90$49,050.00View SEC Filing Icon  
11/13/2020Buy2,000$11.51$23,020.00View SEC Filing Icon  
See Full Table

Steven A. J. Salamon Buying and Selling Activity at Delcath Systems

This chart shows Steven A J Salamon's buying and selling at Delcath Systems by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Delcath Systems Company Overview

Delcath Systems logo
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Read More

Today's Range

Now: $4.83
Low: $4.76
High: $5.05

50 Day Range

MA: $4.34
Low: $3.72
High: $5.09

2 Week Range

Now: $4.83
Low: $2.25
High: $7.99

Volume

172,310 shs

Average Volume

217,288 shs

Market Capitalization

$106.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.51